Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales - MarketWatch
1. BDX stock fell over 15% due to cuts in research funding. 2. Tariffs may reduce earnings by 25 cents per share in 2025. 3. Adjusted profit guidance is now below analysts' expectations. 4. Revenue growth missed estimates, suggesting declining demand. 5. Diagnostics division also facing significant headwinds.